Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study.
about
Safety of extended treatment with anakinra in patients with rheumatoid arthritisIncidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritisLong-term safety and efficacy of infliximab for the treatment of ankylosing spondylitisWhat is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphomaMolecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapiesAntitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.Increased risk for cancer following sarcoidosis.Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis.Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment.The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study.Change in the treatment strategy for pediatric Crohn's diseaseAssociation of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort.Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160Tumor necrosis factor inhibitors - state of knowledge.Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: a case report.Risk of cancer among rheumatoid arthritis patients in California.Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis.Secondary immune deficiencies associated with biological therapeutics.Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis.No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset.Cancer incidence among patients with ankylosing spondylitis in Sweden 1965-95: a population based cohort study.Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).Advances in targeted therapy: safety of biological agentsHaematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis.Risk of lymphoma in patients with RA treated with anti-TNFalpha agents.Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.The British Society for Rheumatology biologics register.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Risk of haematopoietic cancer in patients with inflammatory bowel disease.Long term safety of etanercept in elderly subjects with rheumatic diseases.Swedish registers to examine drug safety and clinical issues in RA.Decreased density of serotonin 5-HT2A receptors in rheumatoid arthritisSafety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
P2860
Q24675209-234E345F-FE82-4DD3-99E9-2B542C05CE0FQ24675306-96CC897A-4446-4E98-B8C4-6FBC3EDFB5FBQ26774173-0D799B13-5C29-4856-82D4-EC92CFC272E3Q28074148-589263E4-0B6F-48C7-BBEE-324E2E82F518Q28177001-3E814AE9-FED0-4D6D-8A14-0BC7069CE599Q33629320-97CCD174-540C-4A23-B3D3-B93703D24EA6Q33641577-13D4292E-D270-48C4-A9CE-25F0076655F8Q33873620-B71965C4-1D56-4B19-BB0E-C79D99F6A51BQ33879770-727A6E42-24F9-48C6-870E-2F268EFF41B8Q34181975-E07FC8CE-4E39-4B85-BD82-384BD9F0E437Q34319316-4BB46945-B9DA-4CA4-A699-A6232C60C17FQ34363241-A2ABC354-8BD1-4479-8112-F094430880FFQ34420755-E647446F-70A1-4B48-A167-21CA9585C0D2Q34498486-7531D387-460A-4EF0-BB2A-331EDF987669Q34628409-F0E469BC-A15F-4673-9CA8-40E2693BA1DFQ34637048-25AC9256-0F3F-4026-8930-C0D21C43B4F4Q34974335-CB2C2C5D-02BC-4A7D-9A02-C90DB0321239Q35144770-0199E9DD-D9CD-49FB-9F8E-540DF7E21BBDQ35162890-9740124D-37AE-4BA2-A2D2-515150BB5102Q35194346-933599B7-2D3A-4C39-A84F-D48E73B89C74Q35195224-C1C82F12-F592-4A79-8F9A-482446A8A9FDQ35216972-FC5294BA-4CC7-4746-A5C4-CB308A364825Q35549071-C24FDBEC-00F3-4568-8ED5-0008842BC4DBQ35552253-A1F6F0BB-C078-4828-B775-37542CAB6648Q35553371-259BAC26-7482-4780-A4DE-5F2FCE6D03F4Q35553451-65605CC6-97BA-458C-9146-7F103B9778DDQ35553474-C8BE90C3-1F3F-4CB0-9233-031AE60A7BBEQ35554823-6D2CD758-EE20-4659-AACA-5366B90B659EQ35555044-4ECD609C-6F10-4C8E-829B-DD5D43F5421FQ35555473-BDE5594F-8D1B-4061-8B22-63AA6122CF89Q35555527-51EB7A41-6699-4EE5-8E57-877D208B2FC4Q35579352-94787C20-DBFD-4A1B-807A-57947E5DF311Q35579512-B556D8FD-0001-4E28-A6A6-CD1FBCE19FE6Q35579517-F282BD1F-05F4-485D-8DE1-AC6425AE5BC5Q35597348-D96B0542-12D3-4980-B468-78DACB52DDFDQ35636875-A0A5EB4F-A789-491C-96E7-FEDCE3772CBAQ35637262-D694298F-9A32-4BF6-832E-383AF9F4B023Q35637276-8D8D8184-027A-43A0-B328-476F3071D543Q35637322-361B5563-6EA9-4984-8192-6C905734E4FDQ35638252-0526832E-6818-43B0-B727-8818C5AACF46
P2860
Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Disease activity and risk of l ...... is: nested case-control study.
@en
type
label
Disease activity and risk of l ...... is: nested case-control study.
@en
prefLabel
Disease activity and risk of l ...... is: nested case-control study.
@en
P2093
P2860
P356
P1433
P1476
Disease activity and risk of l ...... is: nested case-control study.
@en
P2093
E Baecklund
N Feltelius
P2860
P304
P356
10.1136/BMJ.317.7152.180
P407
P577
1998-07-01T00:00:00Z